Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

On March 6, 2024 Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, reported the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California (Press release, Cidara Therapeutics, MAR 6, 2024, View Source [SID1234640851]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are summarized below:

Abstract Title: Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model
Presenter: James Levin, Ph.D.
Session Category: Immunology
Session Title: Single Target and Bispecific Antibodies
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 19, Section 6

Abstract Title: CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathway
Presenters: Amanda Almaguer and Doug Zuill
Session Category: Immunology
Session Title: Immune Checkpoints and Inhibitory Molecules 2
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 22, Section 4

Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
Presenter: Simon Döhrmann, Ph.D.
Session Category: Immunology
Session Title: Single Target and Bispecific Antibodies
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 22, Section 6

Abstract Title: CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization
Presenters: Elizabeth Abelovski and Nicholas Dedeic, Ph.D.
Session Title: Late-Breaking Research: Immunology 2
Date and Time: Monday, April 8, 2024, 9:00 AM-12:30 PM PT
Poster Board Number: 19, Section 52